IFNB1 and myeloid sarcoma: For example, adverse neuropsychiatric outcomes were an early concern for the use of interferon betas in MS, the first class of disease-modifying therapies for relapsing-remitting MS, following the attempted suicides of five participants in a pivotal trial, all in the active interferon beta-1b treatment arm [32].